![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:0616V Cambridge Antibody Tech Group PLC 1 December 2000 For further information contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263233 David Chiswell, CEO John Aston, Finance Director Rowena Gardner, Head of Corporate Communications HCC De Facto (Europe) Tel: +44 (0) 20 7496 3300 Nikul Odedra (trade) Sue Charles (city/financial) Immunex Corporation Tel: 001 206 389 4363 Mark R. Leahy, Director, Investor Relations Kris Greco, Manager, Communications BMC Communications/The Trout Group (USA) Tel: 001 212 477 9007 Brad Miles, ext.17 (media) Brandon Lewis, ext.15 (investors) CAMBRIDGE ANTIBODY TECHNOLOGY PARTNERS WITH IMMUNEX CORPORATION TO DEVELOP NOVEL HUMAN MONOCLONAL ANTIBODIES Commitment to the custom development of human antibody-based therapeutics Melbourn, UK Cambridge Antibody Technology (LSE: CAT) today announced an agreement with Immunex Corporation (NASDAQ: IMNX) to license CAT's proprietary antibody phage display library for the discovery, development and potential commercialisation of human monoclonal antibodies. Under the terms of the agreement, CAT will receive a licence fee from Immunex to utilise the antibody library for reagent generation and target validation in support of drug discovery programmes at Immunex. In addition, Immunex will receive eight exclusive therapeutic antibody product options and CAT will receive clinical milestones and royalty payments on product sales. Further financial details were not disclosed. Dr. David Chiswell, Chief Executive Officer of CAT commented "We are delighted to be joining forces with Immunex in the validation of human disease-associated targets and the development of human monoclonal antibody-based drugs. CAT shares with Immunex the view that the significant long-term value in novel human proteins to treat human disease is best captured through collaborative, strategic partnerships. Furthermore, CAT believes that tailoring human monoclonal antibodies to target fundamental physiological processes in disease is the future of successful drug development." Doug Williams, PhD, Executive Vice President and Chief Technology Officer of Immunex added, "Immunex is pleased to have access to the CAT library. Our research programs in target validation and the development of fully human monoclonal antibodies as therapeutics will be significantly advanced as a result of this alliance." CAT is the world leading company in fully human antibodies derived by phage display and is developing proprietary antibody-based products, both independently and in partnership, as powerful drug discovery tools and for therapeutic application in man. CAT has previously entered into broad strategic alliances for the discovery and development of human monoclonal antibody-based drugs with a number of leading pharmaceutical and biotechnology companies, most recently with Pharmacia Corporation and Human Genome Sciences. Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations. Notes to Editors: Cambridge Antibody Technology (LSE: CAT) CAT is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs nearly 200 people. CAT is listed on the London Stock Exchange, having raised #41m in its IPO in March 1997. A secondary offering in March 2000 raised #93m. CAT has a world-leading platform technology for rapidly isolating fully human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programs and for discovering new drug leads using functional genomics. Four fully human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT works in partnership with other companies at all stages of the drug discovery and development process. CAT's collaborations, past and present, include: AstraZeneca, BASF Pharma, Eli Lilly, Genentech, Genetics Institute, Genzyme, Human Genome Sciences, Oxford GlycoSciences, Pharmacia Corporation, Pfizer, Wyeth-Ayerst Immunex Corporation Immunex Corporation is a biopharmaceutical company based in Seattle, Washington, and has nearly 1500 employees in the United States. The company discovers, develops, manufactures and markets innovative therapeutic products for the treatment of human diseases, including cancer and immunological disorders such as rheumatoid arthritis. The company's research focus has produced a pipeline of potential products that targets some of the most serious medical challenges people face, including cancer, multiple sclerosis, heart disease and asthma.
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions